The Galician Healthcare Service (Sergas) and Gileade have agreed to collaborate in the FOCUS program, an initiative that attempts to eliminate the spread of bloody viruses such as HIV and viral hepatitis (B and C). It is a public health program developed from 2010 in the United States and has conducted over eight million blood studies for HIV, Hepatitis C and Hepatitis B.
The FOCUS program makes it possible to initiate the detection of these infections through integration of HIV and hepatitis c screening tests with other tests into a routine clinical circuit.
The implementation of this initiative is a more example of the further efforts of Xunta de Galicia towards public health policy. In the name of Gilead, it is a clear commitment to promoting collaboration with healthcare providers and thus contributing to the realization of public health emergencies in this disease.
This program is a response to & # 39; s recommendations from & # 39; A World Heritage Organization on the elevation of screening and of UNAIDS, which was published in 2014, was diagnosed with 90% goals, 90% in treatment and 90% on the virus. However, it responded to & # 39; s recommendations e HCV from the Global Health Sector Strategy – GHSS, for its acronym in English – that eliminates viral hepatitis, as one of & # 39; a major public health threat thru the year 2030.
About Gilead Sciences
Gilead Sciences Inc. is a biopharmaceutical research company focused on the discovery, development and commercialization of innovative medicines in areas of medical need. The company strives to process and replenish care for people with worldwide syndicates worldwide. Gilead has a presence in more than 35 countries around the world and its head office is located in Foster City, California.